Skip to main content
. Author manuscript; available in PMC: 2017 Aug 21.
Published in final edited form as: AJR Am J Roentgenol. 2017 May 2;209(2):277–288. doi: 10.2214/AJR.17.18264

Fig. 4.

Fig. 4

Excellent response to 177Lu prostate-specific membrane antigen (PSMA)-617 therapy in man with extensive metastatic castration-resistant prostate cancer. Gallium-68 PSMA PET/CT was performed at baseline before first, after second, and after fourth cycles of therapy show disappearance of all lesions after fourth therapy cycle. CT did not show major morphologic changes in bone metastases. (Used with permission from [132])